🇺🇸 FDA
Patent

US 12209116

Recombinant human C1 esterase inhibitor and uses thereof

granted A61KA61K38/00A61K38/57

Quick answer

US patent 12209116 (Recombinant human C1 esterase inhibitor and uses thereof) held by Takeda Pharmaceutical Company Limited expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K38/00, A61K38/57, A61K9/19, A61P